| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;112:3569-3576.)
© 2005 American Heart Association, Inc.
Heart Disease in Africa |
From Cardiovascular Medicine (T.A.G.) and the Division of Social Medicine and Health Inequalities (T.A.G., M.C.W.), Brigham & Womens Hospital, Harvard Medical School, Boston, Mass; Chronic Diseases of Lifestyle Unit of the Medical Research Council (K.S.), Cape Town, South Africa; Cardiology Division (D.J.C.), Beth Israel Deaconess Medical Center, Boston, Mass; Hatter Institute (L.H.O.), Department of Medicine and Cape Heart Centre, Faculty of Health Sciences, University of Cape Town, South Africa; and Department of Health Policy and Management (M.C.W.), Harvard School of Public Health, Boston, Mass.
Reprint requests to Thomas A. Gaziano, MD, Cardiovascular Medicine, Brigham & Womens Hospital, 75 Francis St, Boston, MA 02115. E-mail tgaziano{at}partners.org
Received January 12, 2005; revision received May 19, 2005; accepted July 18, 2005.
Background Hypertension is responsible for more deaths worldwide than any other cardiovascular risk factor. Guidelines based on blood pressure level for initiation of treatment of hypertension may be too costly compared with an approach based on absolute cardiovascular disease (CVD) risk, especially in developing countries.
Methods and Results Using a Markov CVD model, we compared 6 strategies for initiation of drug treatment2 different blood pressure levels (160/95 and 140/90 mm Hg) and 4 different levels of absolute CVD risk over 10 years (40%, 30%, 20%, and 15%)with one of no treatment. We modeled a hypothetical cohort of all adults without CVD in South Africa, a multiethnic developing country, over 10 years. The incremental cost-effectiveness ratios for treating those with 10-year absolute risk for CVD >40%, 30%, 20%, and 15% were $700, $1600, $4900, and $11 000 per quality-adjusted life-year gained, respectively. Strategies based on a target blood pressure level were both more expensive and less effective than treatment decisions based on the strategy that used absolute CVD risk of >15%. Sensitivity analysis of cost of treatments, prevalence estimates of risk factors, and benefits expected from treatment did not change the ranking of the strategies.
Conclusions In South Africa, current guidelines based on blood pressure levels are both more expensive and less effective than guidelines based on absolute risk of cardiovascular disease. The use of quantitative risk-based guidelines for treatment of hypertension could free up major resources for other pressing needs, especially in developing countries. (Circulation. 2005;112:3569-3576.)
Key Words: cost-benefit analysis hypertension prevention stroke cardiovascular diseases
This article has been cited by other articles:
![]() |
G A Mensah Ischaemic heart disease in Africa Heart, July 1, 2008; 94(7): 836 - 843. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Alcocer and L. Cueto Review: Hypertension, a health economics perspective Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 147 - 155. [Abstract] [PDF] |
||||
![]() |
G A Mensah Epidemiology of stroke and high blood pressure in Africa Heart, June 1, 2008; 94(6): 697 - 705. [Abstract] [Full Text] [PDF] |
||||
![]() |
T A Gaziano Economic burden and the cost-effectiveness of treatment of cardiovascular diseases in Africa Heart, February 1, 2008; 94(2): 140 - 144. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Gaziano Reducing The Growing Burden Of Cardiovascular Disease In The Developing World Health Aff., January 1, 2007; 26(1): 13 - 24. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. H. Opie and B. M. Mayosi Cardiovascular Disease in Sub-Saharan Africa Circulation, December 6, 2005; 112(23): 3536 - 3540. [Full Text] [PDF] |
||||
![]() |
L. H. Opie and Y. K. Seedat Hypertension in Sub-Saharan African Populations Circulation, December 6, 2005; 112(23): 3562 - 3568. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |